Ruxolitinib not checked

Novartis · INCB018424 cream · INCB018424 phosphate cream

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 3 trial completes
Trials
30 active
84 in total · 30 in the EU
Targets
 

What this is

How it works
Blocks JAK enzymes that pass on immune signals, to calm an overactive immune system.Kinase Inhibitor; Janus Kinase Inhibitor FDA class
How it’s given
“Ruxolitinib is taken orally daily at 10 mg BID, given as two 5-mg tablets.”In the company’s words, NCT06462469 on ClinicalTrials.gov
Tested for
Hidradenitis Suppurativa (3 trials), Primary Myelofibrosis (2 trials), Myelofibrosis (2 trials), NonSegmental Vitiligo (2 trials), Primary Myelofibrosis (PMF) (2 trials), Myeloproliferative Neoplasms (2 trials), Steroid-refractory Acute Graft Versus Host Disease, Graft vs. Host Disease and 29 more
Main trialPhase 4
“The purpose of this study is to assess the efficacy and safety of ruxolitinib therapy in Chinese adults and adolescents (≥ 12 years old) with Grade II-IV steroid-refractory acute graft versus host disease (SR-aGvHD).”In the company’s words, NCT06462469 on ClinicalTrials.gov
Other names
INCB018424 cream · INCB018424 phosphate cream · Opzelura · INCB18424 cream · INCB018424 · Oral Jak Inhibitor · Jakafi · Jakavi · INC424 · Jakavi/Jakafi
Given with
Diprolene (Organon), Dovonex (LEO Pharm)Other companies’ drugs in its trials

Other drugs for Hidradenitis Suppurativa

All 29 drugs for Hidradenitis Suppurativa

Copies tested against it1

Other companies’ versions, mostly cheaper copies for when the patent ends

Coming up12

Changes3

Last 90 days

Trials84

TrialPhaseCompletesWhat it tests
Phase 4Active, not recruiting 3 Sep 2026 Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease
Phase 4Recruiting 10 May 2029 Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
Phase 4Active, not recruiting 5 Apr 2032 CINC424A2X01B Rollover Protocol
Phase 3Active, not recruiting 23 Aug 2023 Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
Phase 3Active, not recruiting 7 Aug 2026 A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
Phase 3Active, not recruiting 1 Oct 2026 Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
Phase 3Active, not recruiting 29 Oct 2026 Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
Phase 3Recruiting 30 Apr 2027 A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Phase 3Recruiting 17 May 2028 A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Phase 3Recruiting 5 Jun 2028 A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Phase 3Recruiting 31 Dec 2029 An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Phase 3Recruiting 17 Jan 2031 A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Phase 2Active, not recruiting 1 Oct 2026 A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
Phase 2Active, not recruiting 5 Nov 2026 Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Phase 2Active, not recruiting 30 Sep 2027 An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Phase 1Active, not recruiting 23 Jul 2026 Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Phase 1Recruiting 9 Dec 2026 Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
Phase 1Active, not recruiting 30 Apr 2027 Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Phase 1Active, not recruiting 29 Feb 2028 A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Phase 1Recruiting 29 Oct 2028 A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Phase 4Terminated 22 Jan 2025 The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.
Phase 3Completed 29 Sep 2015 Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.
Phase 3Completed 24 Jun 2019 Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Phase 3Completed 18 Nov 2019 TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
Phase 3Completed 23 Dec 2019 Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
Phase 3Completed 8 May 2020 A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Phase 3Completed 17 Oct 2020 Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm
Phase 3Terminated 26 Feb 2021 Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
Phase 3Completed 15 Mar 2021 Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)
Phase 3Completed 18 Mar 2021 Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
Phase 3Completed 14 Nov 2022 Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
Phase 3Completed 10 May 2023 A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)
Phase 3Terminated 3 Aug 2023 To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Phase 3Terminated 16 Aug 2023 To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
Phase 3Withdrawn 25 Apr 2024 Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1
Phase 3Withdrawn 25 Apr 2024 Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2
Phase 3Completed 17 May 2024 Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis
Phase 3Completed 7 Oct 2024 A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
Phase 3Completed 30 Dec 2024 A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
Phase 3Completed 21 May 2025 A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
Phase 2Completed 31 Jan 2009 A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis
Phase 2Completed 30 Apr 2009 Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis
Phase 2Completed 26 Jun 2009 A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis
Phase 2Terminated 20 Jun 2010 Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia
Phase 2Completed 10 Jan 2018 A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
Phase 2Completed 31 Jan 2018 A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
Phase 2Completed 12 Sep 2018 A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
Phase 2Completed 14 Mar 2020 A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
Phase 2Terminated 3 Aug 2020 Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Phase 2Terminated 28 Jan 2021 A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Phase 2Completed 25 Feb 2022 Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant
Phase 2Completed 17 Nov 2022 A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)
Phase 2Completed 18 Nov 2022 The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis
Phase 2Completed 3 Aug 2023 Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement
Phase 2Completed 1 Sep 2023 A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus
Phase 2Completed 2 Oct 2023 A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus
Phase 2Completed 19 Oct 2023 Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
Phase 2Completed 15 Jul 2024 Topical Ruxolitinib Evaluation in Chronic Hand Eczema
Phase 2Completed 6 Mar 2025 A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo
Phase 2Completed 3 Mar 2026 A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Phase 1/2Terminated 13 Feb 2019 Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2Terminated 11 Aug 2020 Study of INCB053914 in Subjects With Advanced Malignancies
Phase 1/2Completed 11 Mar 2021 Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease
Phase 1/2Terminated 3 May 2023 Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
Phase 1/2Completed 1 Apr 2025 INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Phase 1Completed 31 Dec 2019 Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)
Phase 1Completed 22 Jun 2020 Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis
Phase 1Completed 9 Nov 2020 Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis
Phase 1Completed 7 Aug 2023 Study of Ruxolitinib Cream in Children With Atopic Dermatitis
Phase 1Completed 16 Apr 2024 A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.
Phase 1Completed 25 Oct 2024 A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants
Phase 1Completed 8 Sep 2026 A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
Phase 1/2Authorised not given International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children - Sub-protocol C
Phase 2Ended not given JAKAHDI - JAK inhibitors in acquired hemophagocytic syndrome in the ICU
Phase 2Authorised not given BIGTIM: Blocking Interferon-γ by ruxolitinib for Treating Inclusion body Myositis: a phase IIb trial.
Phase 2Authorised not given Phase 2 Trial to determine the safety and efficacy of simultaneous treatment with ruxolitinib and extracorporeal photopheresis for patients with steroid-refractory chronic Graft-versus-Host-Disease (SR-cGvHD) - RUX-ECP
Phase 1Ended not given Comparative Bioavailability of Ruxolitinib 20 mg Film-Coated Tablets: A Single-Dose, Open-Label, Randomized, Two-Treatment, Two-Sequence, Two-Period Crossover Study in Healthy Participants Under Fasting Conditions.
Phase 2Authorised not given Ruxolitinib versus Best Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The Ruxo-BEAT Trial
Phase 2Authorised not given R-HLH - Efficacy of Ruxolitinib as first line treatment in primary haemophagocytic lymphohistiocytosis (HLH) in children: a Phase 2, multicentre, non-comparative study
Phase 3Authorised not given MITHRIDATE: A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha as first line ThErapy for high risk polycythemia vera
Phase 2Authorised not given Combination Therapy with Interferon-Alpha2a and Ruxolitinib in Newly Diagnosed Patients with Polycythemia Vera. A Danish Safety and Efficacy Study.
Phase 2/3Authorised not given Ruxolitinib for childhood ALL in Poland (Rux-cALL-Pol 2020 trial) - Single-arm interventional study with ruxolitinib and AIEOP-BFM 2017 Poland or AIEOP-BFM 2017 standard of care chemotherapy in children with acute lymphoblastic leukemia and confirmed activation of JAK/STAT pathway.
Phase 2Authorised not given A phase-2 academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or pembrolizumab in relapsed or refractory classical Hodgkin lymphoma (cHL)
Phase 2/3Authorised not given Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Ruxolitinib

Following is part of Solo: you see every change to Ruxolitinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in